Nuvectis Pharma, Inc. 8-K

What Happened

• On June 22, 2026, Nuvectis Pharma, Inc. announced it entered into an exclusive, royalty-bearing License Agreement with Haisco Pharmaceutical Group Co., Ltd. The license grants Nuvectis development, manufacturing and commercialization rights in the defined Territory for HSK39297 (NXP100), a Complement Factor B inhibitor, and HSK42360 (NXP200), a BRAF inhibitor. Haisco will remain responsible for ongoing development in China and will receive a share of sublicensing revenue in the Territory.

Key Details

• Upfront payment: $20 million paid to Haisco at signing.
• Near-term milestones: up to $20 million in initial development milestones tied to early clinical events.
• Potential contingent payments: up to $1.4 billion tied to future development, regulatory and commercial milestones.
• Royalties: tiered royalties in the high-single digits to mid-teens on net sales in the Territory (subject to reductions in certain cases).
• Territory: NXP100 rights exclude China, Hong Kong, Macau, Taiwan and several Southeast Asian countries listed in the agreement; NXP200 rights exclude China, Hong Kong, Macau and Taiwan.
• Other terms: license becomes effective subject to certain financing conditions; change-of-control fee to Haisco (low double-digit percentage of fair market value) if a change of control occurs within 18 months; restrictions on exploiting non-licensed BRAF or Factor B products (with customary acquirer exception).

Why It Matters

• This deal gives Nuvectis rights to two late-stage drug candidates and adds potential near-term and long-term value drivers: an immediate $20M upfront obligation and material upside through milestone and royalty payments (up to $1.4B plus royalties). For investors, key items to watch are the company’s required financing (the agreement is subject to financing conditions), progress on the licensed candidates’ clinical development, and any sublicensing or commercialization milestones that could generate revenue. The agreement also preserves Haisco’s China development, limiting Nuvectis’s territory but allowing global commercialization outside the specified exclusions.